Introduction Recro Pharma (NASDAQ: REPH) engages in the research and development of non-opioid therapeutics for the treatment of acute postoperative pain. REPH is currently developing three … [Read more...] about $REPH – Recro Pharma, PDUFA Swing Trade
Swing Trades
MS Identified Its Next Swing
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Preface WOW. We are absolutely elated with the performance of our last swing move on SCYX. In case you missed it on … [Read more...] about MS Identified Its Next Swing
SCYX Swing Move
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. Swing Thesis SCYNEXIS (Nasdaq: SCYX $.73) has been identified as a potentially lucrative swing move. … [Read more...] about SCYX Swing Move
Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
After a little research it appears that shorts are working overtime to hold Catalyst Pharmaceuticals (Nasdaq: CPRX) under $3.0. Only 5 days ago we were at $3.20. A month ago and before the PDUFA date … [Read more...] about Shorts Fighting To Keep CPRX from Gaining Momentum-Insiders Aren’t Phased
A Question about ACRX price decline after Dsuvia approval
Question by deadpool from StockTwits: Q: "how do you feel about ACRX price action today seems like just a red market is tearing everything down. i am hopeful we get back up to 3.30s next week" Thanks … [Read more...] about A Question about ACRX price decline after Dsuvia approval
CPRX Swing Move For November 2018
Investment Overview MSMM believes Catalyst Pharmaceuticals (Nasdaq: CPRX $2.88) is a good swing-move for the remainder of November of 2018. The company has a PDUFA action date on November 28th … [Read more...] about CPRX Swing Move For November 2018
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
2 ACRX Insiders Sold For Massive Gains, 4 others Bought and Held-Shareholders Turn is Next
Tuesday October 16th, 2018 AcelRx Pharmaceuticals (NASDAQ: ACRX) Chief Development Officer (CDO) and Chief Engineer reported selling an aggregate of 33,567 shares at $5 per share. The month before the … [Read more...] about 2 ACRX Insiders Sold For Massive Gains, 4 others Bought and Held-Shareholders Turn is Next
ACRX Update-Strong Hold
We did indeed call the swing. ACRX was trading at around$2.90 when we identified it as a good swing-trade candidate. Currently it is trading around $4.54 making for a healthy 55% gain. Where I was … [Read more...] about ACRX Update-Strong Hold
ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It
MS Money Moves Swing thesis for AcelRX Pharma (ACRX) published last week in our "Swing Alert"article played out nicely. ACRX spiked ~70% from $2.90 to $4.92 in the last 5 trading sessions. The upward … [Read more...] about ACRX to Spike Monday off Favorable ADCOM Vote 10-3: How to Handle It
